Ipratropium bromide/salbutamol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ipratropium bromide/salbutamol
Combination of
Ipratropium bromide Muscarinic antagonist
Salbutamol Short-acting β2-adrenergic agonist
Clinical data
Pregnancy
category
Routes of
administration
Inhalation
ATC code
Legal status
Legal status
  • AU: S3 (Pharmacist only)
  • UK: POM (Prescription only)
  • US: ℞-only
  (verify)

The combination preparation ipratropium bromide/salbutamol is a formulation containing ipratropium bromide (an anticholinergic) and salbutamol sulfate (albuterol sulfate, a β2-adrenergic receptor agonist) used in the management of chronic obstructive pulmonary disease (COPD) and asthma (not an FDA approved usage).[2] It is marketed by Boehringer Ingelheim as a metered dose inhaler (MDI) and nebuliser under the trade name Combivent. It is also marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb as a nebulizer. In Italy it is known as Breva. The chemical is sold in India by Cipla as duolin. [3]

Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries. Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer.

External links[edit]

References[edit]

  1. ^ http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Combivent+IA/combivent.pdf
  2. ^ "Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma.". ): National Institutes of Health. National Heart, Lung, and Blood Institute. 2007. 
  3. ^ http://www.cipladoc.com/therapeutic/admin.php?mode=prod&action=disp&id=240
  • National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.